Brivanib is a small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR), inhibiting tumor angiogenesis and growth. It is primarily investigated for the treatment of advanced solid tumors, including hepatocellular carcinoma.

Brivanib API is manufactured and supplied by ASTANDARDS | Artis Biotech, ensuring high purity, consistent quality, and regulatory-compliant specifications. Our APIs are produced using validated processes and are suitable for research, development, and pharmaceutical manufacturing applications.